You are here: Industry Insights > Seegene

News List

Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil prnasia
February 11, 2022
Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.
Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing prnasia
January 20, 2022
Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex? SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes.
Seegene's Allplex? SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order prnasia
January 18, 2022
Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex? SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order on January 11.
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube prnasia
December 10, 2021
Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape.
Seegene Announces Q3 2021 Earnings, Continuing COVID-Era Momentum prnasia
November 24, 2021
Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx) has announced financial results for the third quarter ended September 30, 2021.
Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing prnasia
October 28, 2021
South Korea's leading molecular diagnostics (MDx) developer Seegene Inc., (KQ 096530) is addressing the needs of small, mid-sized, and large hospitals and COVID-19? laboratories with its fully automated STARlet-AIOS...
Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus americanpharmaceuticalreview
July 14, 2021
Seegene Inc, a South Korean biotechnology firm, announced the launch of a SARS-CoV-2 variant diagnostic test capable of detecting new virus variants including the Delta and the Delta Plus that have become the dominant virus around the world.
Seegene signs exclusive supply agreement with the Kuwaiti government prnasia
May 18, 2021
Seegene Inc., South Korea's largest molecular diagnostics firm, will be supplying COVID-19 diagnostic kits worth over $4.8 million to the Kuwaiti government.
Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion prnasia
May 12, 2021
Seegene Inc., a molecular diagnostics company reported its financial results for the first quarter of 2021, with reports showing robust earnings.
Seegene's Germany subsidiary supports the back-to-school initiative with its COVID-19 tests prnasia
May 11, 2021
Seegene Inc. (KQ 096530), a leading molecular diagnostics firm said its German subsidiary, Seegene Germany GmbH is taking part in the government's Back-to-School program called the "Lolli-Test," a starting point in returning our daily lives back to ...